Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

2.760 +0.020 (+0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Curevac N.V.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
28 Stocks Moving in Friday's Pre-Market Session
Gainers CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc. Geron... 
Via Benzinga
12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer
The news may reinforce Moderna's and Pfizer's vaccine-market dominance. 
Via The Motley Fool
Topics Supply Chain
Exposures COVID-19 Supply Chain
Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data
CureVac N.V.’s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the... 
Via Benzinga
Exposures COVID-19
Mid-Afternoon Market Update: Nasdaq Gains Over 100 Points; CureVac Shares Plummet
Toward the end of trading Thursday, the Dow traded down 0.67% to 33,806.27 while the NASDAQ rose 0.91% to 14,167.03. The S&P also fell, dropping 0.02% to 4,222.94. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why CureVac's Stock Is Trading Higher Today
CureVac (NASDAQ:CVAC) shares are trading higher ... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Verve Therapeutics, Inc. (NASDAQ: VERV) shares surged 68% to settle at $31.92 on Thursday after the company priced its IPO at $19 per share. Midatech Pharma plc (NASDAQ... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Dow Plummets as Fed Update, Jobless Data Weighs
The Federal Reserve's accelerated interest rate timeline and inflation forecast is putting a damper on stocks today, with worse-than-expected weekly jobless claims only adding insult to injury. 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Mid-Day Market Update: Gold Drops Over 4%; Midatech Pharma Shares Jump
Midway through trading Thursday, the Dow traded down 0.35% to 33,913.86 while the NASDAQ rose 0.73% to 14,142.60. The S&P also rose, gaining 0.07% to 4,226.52. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
34 Stocks Moving In Thursday's Mid-Day Session
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger... 
Via Benzinga
Why CureVac Stock Is Getting Crushed Today
The biotech's COVID-19 vaccine candidate no longer appears to be viable. 
Via The Motley Fool
Exposures COVID-19
Mid-Morning Market Update: Markets Mixed; Kroger Earnings Top Views
Following the market opening Thursday, the Dow traded down 0.29% to 33,935.28 while the NASDAQ rose 0.34% to 14,086.74. The S&P also fell, dropping 0.01% to 4,223.07. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
CureVac Stock Plummets After Covid Vaccine Fails In Interim Analysis
CureVac stock plummeted Thursday after its messenger RNA-based Covid vaccine failed in an interim analysis. The vaccine was 47% effective against Covid of any severity. 
Via Investor's Business Daily
Exposures COVID-19
CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today
CureVac shares crashed after the German biotech said its Covid-19 vaccine was only 47% effective in preventing the disease. 
Via InvestorPlace
Exposures COVID-19
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19
25 Stocks Moving in Thursday's Pre-Market Session
Gainers Midatech Pharma plc (NASDAQ: MTP) rose 42.2% to $2.90 in pre-market trading after the company disclosed breakthrough data using Q-Sphera technology. Cellect... 
Via Benzinga
Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data
German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ: BNTX), which along with its... 
Via Benzinga
Exposures COVID-19
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent - At second interim analysis, statistical... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Unusual Options Activity Insight: CureVac
CureVac (NASDAQ:CVAC) shares experienced unusual options activity on Wednesday. The stock price moved up to $99.74 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
Moderna, BioNTech Pop Despite Mounting Pressure On Covid Vaccine Patents
The World Trade Organization is moving ahead with a plan that could waive Covid vaccine patents. But vaccine stocks weren't rattled Thursday. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
75 Biggest Movers From Yesterday
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on Tuesday amid increased retail investor interest in the stock. NextDecade... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Thor Industries Beats Q3 Estimates
Following the market opening Tuesday, the Dow traded down 0.16% to 34,574.38 while the NASDAQ rose 0.32% to 13,926.79. The S&P also fell, dropping 0.04% to 4,224.95. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares jumped 72.4% to $20.55 amid increased retail investor interest in the stock. NextDecade Corporation (NASDAQ: NEXT... 
Via Benzinga
Could CureVac Be a Millionaire-Maker Stock?
This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in. 
Via The Motley Fool
Exposures COVID-19
CureVac Appoints Klaus Edvardsen as Chief Development Officer
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.... 
Via Benzinga
Exposures COVID-19
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases - Sequencing data to be made available in parallel with efficacy data given... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
- First-Generation COVID-19 vaccine program, CVnCoV - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-... 
Via Benzinga
Exposures COVID-19
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK - CV2CoV mRNA shows high levels of antigen production in rat model - Fast onset of strong... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.